Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Chronic Lymphocytic Leukemia

Doubling time of soluble CD23: a powerful prognostic factor for newly diagnosed and untreated stage A chronic lymphocytic leukemia patients

Leukemia volume 22, pages 1882–1890 (2008)Cite this article

Abstract

Soluble CD23 (sCD23) levels correlate with the stage, prognosis and overall survival (OS) of patients with chronic lymphocytic leukemia (CLL). Therefore, we prospectively evaluated sCD23 doubling time (sCD23DT) as a prognostic factor for time to treatment (TTT) and OS in 56 newly diagnosed and untreated CLL patients at Binet stage A, and compared it to the most commonly used biological prognostic factors: lymphocyte doubling time, immunoglobulin variable heavy chain (IgVH) mutational status and ζ-associated protein-70 (ZAP-70), CD38, and lipoprotein lipase (LPL) expression. In patients with sCD23DT <1 year, the median TTT and OS were 20 and 83 months compared to 141 and 177 months in patients with sCD23DT >1 year (P<0.0001). Among patients with poor prognostic factors (ZAP-70+, LPL+ and CD38+), an sCD23DT <1 year identified a subpopulation with a shorter TTT. Patients with unmutated IgVH and an sCD23DT <1 year had a median TTT and OS of 14 and 83 months, respectively, whereas these values were 70 and >177 months when sCD23DT was >1 year (P<0.0001 and P=0.0219, respectively). Finally, in a Cox multivariate analysis, sCD23DT was the sole independent prognostic factor for TTT (P=0.0027). Furthermore, sCD23DT refines the prognosis given by other classical prognostic factors. These observations support the introduction of sCD23 evaluation into the routine assessment of CLL patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Oscier DG, Gardiner AC, Mould SJ, Glide S, Davis ZA, Ibbotson RE et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002; 100: 1177–1184.

    CAS  PubMed  Google Scholar 

  2. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840–1847.

    CAS  PubMed  Google Scholar 

  3. Ghia P, Guida G, Stella S, Gottardi D, Geuna M, Strola G et al. The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood 2003; 101: 1262–1269.

    Article  CAS  PubMed  Google Scholar 

  4. Oppezzo P, Vasconcelos Y, Settegrana C, Jeannel D, Vuillier F, Legarff-Tavernier M et al. The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia. Blood 2005; 106: 650–657.

    Article  CAS  PubMed  Google Scholar 

  5. Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003; 101: 4944–4951.

    Article  CAS  PubMed  Google Scholar 

  6. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348: 1764–1775.

    Article  CAS  PubMed  Google Scholar 

  7. Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, Gribben JG et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004; 351: 893–901.

    Article  CAS  PubMed  Google Scholar 

  8. Zanotti R, Ambrosetti A, Lestani M, Ghia P, Pattaro C, Remo A et al. ZAP-70 expression, as detected by immunohistochemistry on bone marrow biopsies from early-phase CLL patients, is a strong adverse prognostic factor. Leukemia 2007; 21: 102–109.

    Article  CAS  PubMed  Google Scholar 

  9. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK . Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848–1854.

    CAS  PubMed  Google Scholar 

  10. Ghia P, Stamatopoulos K, Belessi C, Moreno C, Stella S, Guida G et al. Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: the lesson of the IGHV3-21 gene. Blood 2005; 105: 1678–1685.

    Article  CAS  PubMed  Google Scholar 

  11. Bomben R, Dal Bo M, Capello D, Benedetti D, Marconi D, Zucchetto A et al. Comprehensive characterization of IGHV3-21-expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study. Blood 2007; 109: 2989–2998.

    CAS  PubMed  Google Scholar 

  12. Orchard JA, Ibbotson RE, Davis Z, Wiestner A, Rosenwald A, Thomas PW et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004; 363: 105–111.

    Article  CAS  PubMed  Google Scholar 

  13. Delespesse G, Sarfati M, Wu CY, Fournier S, Letellier M . The low-affinity receptor for IgE. Immunol Rev 1992; 125: 77–97.

    Article  CAS  PubMed  Google Scholar 

  14. Sarfati M, Bron D, Lagneaux L, Fonteyn C, Frost H, Delespesse G . Elevation of IgE-binding factors in serum of patients with B cell-derived chronic lymphocytic leukemia. Blood 1988; 71: 94–98.

    CAS  PubMed  Google Scholar 

  15. Knauf WU, Ehlers B, Mohr B, Thiel E, Langenmayer I, Hallek M et al. Prognostic impact of the serum levels of soluble CD23 in B-cell chronic lymphocytic leukemia. Blood 1997; 89: 4241–4242.

    CAS  PubMed  Google Scholar 

  16. Zucchetto A, Bomben R, Bo MD, Nanni P, Bulian P, Rossi FM et al. ZAP-70 expression in B-cell chronic lymphocytic leukemia: evaluation by external (isotypic) or internal (T/NK cells) controls and correlation with IgV(H) mutations. Cytometry B Clin Cytom 2006; 70: 284–292.

    Article  PubMed  Google Scholar 

  17. Schwarzmeier JD, Shehata M, Hilgarth M, Marschitz I, Louda N, Hubmann R et al. The role of soluble CD23 in distinguishing stable and progressive forms of B-chronic lymphocytic leukemia. Leuk Lymphoma 2002; 43: 549–554.

    Article  CAS  PubMed  Google Scholar 

  18. Saka B, Aktan M, Sami U, Oner D, Sanem O, Dincol G . Prognostic importance of soluble CD23 in B-cell chronic lymphocytic leukemia. Clin Lab Haematol 2006; 28: 30–35.

    Article  CAS  PubMed  Google Scholar 

  19. Sarfati M, Chevret S, Chastang C, Biron G, Stryckmans P, Delespesse G et al. Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia. Blood 1996; 88: 4259–4264.

    CAS  PubMed  Google Scholar 

  20. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O’Brien S et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–4997.

    CAS  PubMed  Google Scholar 

  21. Chomczynski P, Sacchi N . Single-step method of RNA isolation by acid guanidinium thiocyanate–phenol–chloroform extraction. Anal Biochem 1987; 162: 156–159.

    Article  CAS  PubMed  Google Scholar 

  22. Montserrat E, Sanchez-Bisono J, Vinolas N, Rozman C . Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J Haematol 1986; 62: 567–575.

    Article  CAS  PubMed  Google Scholar 

  23. Stamatopoulos B, Meuleman N, Haibe-Kains B, Duvillier H, Massy M, Martiat P et al. Quantification of ZAP70 mRNA in B cells by real-time PCR is a powerful prognostic factor in chronic lymphocytic leukemia. Clin Chem 2007; 53: 1757–1766.

    Article  CAS  PubMed  Google Scholar 

  24. Domingo-Domenech E, Domingo-Claros A, Gonzalez-Barca E, Beneitez D, Alonso E, Romagosa V et al. CD38 expression in B-chronic lymphocytic leukemia: association with clinical presentation and outcome in 155 patients. Haematologica 2002; 87: 1021–1027.

    PubMed  Google Scholar 

  25. van’t Veer MB, Brooijmans AM, Langerak AW, Verhaaf B, Goudswaard CS, Graveland WJ et al. The predictive value of lipoprotein lipase for survival in chronic lymphocytic leukemia. Haematologica 2006; 91: 56–63.

    PubMed  Google Scholar 

  26. Mertens D, Wolf S, Schroeter P, Schaffner C, Dohner H, Stilgenbauer S et al. Down-regulation of candidate tumor suppressor genes within chromosome band 13q14.3 is independent of the DNA methylation pattern in B-cell chronic lymphocytic leukemia. Blood 2002; 99: 4116–4121.

    Article  CAS  PubMed  Google Scholar 

  27. Campbell MJ, Zelenetz AD, Levy S, Levy R . Use of family specific leader region primers for PCR amplification of the human heavy chain variable region gene repertoire. Mol Immunol 1992; 29: 193–203.

    Article  PubMed  Google Scholar 

  28. Gibbs G, Bromidge T, Howe D, Hopkins J, Johnson S . Comparison of flow cytometric methods for the measurement of ZAP-70 expression in a routine diagnostic laboratory. Clin Lab Haematol 2005; 27: 258–266.

    Article  CAS  PubMed  Google Scholar 

  29. Van Bockstaele F, Pede V, Janssens A, Callewaert F, Offner F, Verhasselt B et al. Lipoprotein lipase mRNA expression in whole blood is a prognostic marker in B cell chronic lymphocytic leukemia. Clin Chem 2007; 53: 204–212.

    Article  CAS  PubMed  Google Scholar 

  30. Heintel D, Kienle D, Shehata M, Krober A, Kroemer E, Schwarzinger I et al. High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia. Leukemia 2005; 19: 1216–1223.

    Article  CAS  PubMed  Google Scholar 

  31. Chevallier P, Penther D, Avet-Loiseau H, Robillard N, Ifrah N, Mahe B et al. CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia. Br J Haematol 2002; 116: 142–150.

    Article  CAS  PubMed  Google Scholar 

  32. Hamblin TJ, Orchard JA, Ibbotson RE, Davis Z, Thomas PW, Stevenson FK et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002; 99: 1023–1029.

    Article  CAS  PubMed  Google Scholar 

  33. Deaglio S, Vaisitti T, Aydin S, Ferrero E, Malavasi F . In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia. Blood 2006; 108: 1135–1144.

    Article  CAS  PubMed  Google Scholar 

  34. Dohner H, Stilgenbauer S, Fischer K, Bentz M, Lichter P . Cytogenetic and molecular cytogenetic analysis of B cell chronic lymphocytic leukemia: specific chromosome aberrations identify prognostic subgroups of patients and point to loci of candidate genes. Leukemia 1997; 11 (Suppl 2): S19–S24.

    PubMed  Google Scholar 

  35. Stilgenbauer S, Dohner K, Bentz M, Lichter P, Dohner H . Molecular cytogenetic analysis of B-cell chronic lymphocytic leukemia. Ann Hematol 1998; 76: 101–110.

    Article  CAS  PubMed  Google Scholar 

  36. Tobin G, Thunberg U, Johnson A, Thorn I, Soderberg O, Hultdin M et al. Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood 2002; 99: 2262–2264.

    Article  CAS  PubMed  Google Scholar 

  37. Reinisch W, Willheim M, Hilgarth M, Gasche C, Mader R, Szepfalusi S et al. Soluble CD23 reliably reflects disease activity in B-cell chronic lymphocytic leukemia. J Clin Oncol 1994; 12: 2146–2152.

    Article  CAS  PubMed  Google Scholar 

  38. Gattei V, Bulian P, Del Principe MI, Zucchetto A, Maurillo L, Buccisano F et al. Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. Blood 2008; 111: 865–873.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank Marika Sarfati and Pierre Heimann for their help and scientific contribution. This work was financed by the Télévie fund, FRIA grant (Fond de Recherche pour l’Industrie et l’Agriculture) both of which are affiliated with the FRS–FNRS (Fonds de la Recherche Scientifique–FNRS) and the MEDIC foundation from Belgian fund for medical scientific research.

Author information

Author notes

  1. N Meuleman and B Stamatopoulos: These authors contributed equally to this work.

Authors and Affiliations

  1. Department of Clinical and Experimental Hematology, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, Belgium

    N Meuleman, B Stamatopoulos, M Dejeneffe, L Lagneaux & D Bron

  2. Department of Molecular Genetics, Hôpital Erasme, Université Libre de Bruxelles (ULB), Brussels, Belgium

    H El Housni

Authors
  1. N Meuleman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B Stamatopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Dejeneffe
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H El Housni
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L Lagneaux
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D Bron
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D Bron.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Meuleman, N., Stamatopoulos, B., Dejeneffe, M. et al. Doubling time of soluble CD23: a powerful prognostic factor for newly diagnosed and untreated stage A chronic lymphocytic leukemia patients. Leukemia 22, 1882–1890 (2008). https://doi.org/10.1038/leu.2008.190

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2008.190

Keywords

This article is cited by

Search

Advanced search

Quick links